Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 46

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Axial spondyloarthritis+4

Recruiting

Study on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Recruiting

Comparison of ocrelizumab and rituximab treatment in adults with active relapsing-remitting multiple sclerosis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Helse Bergen HF

Juvenile spondyloarthritis+2

Recruiting

Study on the Safety and Body Processing of Bimekizumab in Children with Juvenile Idiopathic Arthritis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Rheumatoid arthritis

Recruiting

Study Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Mite allergy

Recruiting

Study on the Effectiveness and Safety of Beltavac for Patients with Allergic Rhinitis from House Dust Mites

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Mixture Of Allergen Extracts Of Dermatophagoides Pteronyssinus And Dermatophagoides Farinae Polymerized With Glutaraldehyde
  • Sponsor:Probelte Pharma S.L.

Acute respiratory distress syndrome

Recruiting

Study on [68Ga]FAPI-46 to Detect Fibroblast Activity in Patients with Non-Resolving Acute Respiratory Distress Syndrome (ARDS) in the ICU

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Universitair Medisch Centrum Groningen

Asthma

Recruiting

Study on Salbutamol and Ipratropium Bromide for Treating Moderate Asthma Attacks in Children

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Ipratropium Bromide Monohydrate
  • Sponsor:Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus

Sjogren's syndrome

Recruiting

Study on the Effectiveness of CL-AD-MSC-002 Injections for Dry Mouth in Patients with Sjögren's Syndrome

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cl-Ad-Msc-002
  • Sponsor:Rigshospitalet

HIV infection

Recruiting

Study on Venetoclax for Reducing HIV Reservoir in Patients on Antiretroviral Therapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Venetoclax
  • Sponsor:Region Midtjylland

Myelin oligodendrocyte glycoprotein antibody-associated disease

Recruiting

Study of Early versus Delayed Treatment with Azathioprine or Rituximab in Children with Anti-MOG Antibody Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Cardiac amyloidosis

Recruiting

Study on the Effects of Valsartan and Sacubitril for Patients with Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sacubitril
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda

Crohn's disease

Recruiting

Study of Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells and Microfat for Patients with Refractory Perianal Crohn's Disease Fistulas

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Regional De Marseille

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.